Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) – Roth Capital issued their FY2029 earnings per share estimates for shares of Aptevo Therapeutics in a report issued on Monday, February 17th. Roth Capital analyst J. Aschoff anticipates that the biotechnology company will earn $2.84 per share for the year. The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($85.96) per share.
Separately, StockNews.com initiated coverage on Aptevo Therapeutics in a research report on Monday, December 9th. They set a “sell” rating on the stock.
Aptevo Therapeutics Stock Performance
Shares of NASDAQ APVO opened at $3.49 on Wednesday. The stock’s 50-day simple moving average is $4.65 and its two-hundred day simple moving average is $241.74. Aptevo Therapeutics has a twelve month low of $3.01 and a twelve month high of $399.60.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Read More
- Five stocks we like better than Aptevo Therapeutics
- Transportation Stocks Investing
- Affirm Hits Profitability—Here’s What Investors Should Watch
- What is a Stock Market Index and How Do You Use Them?
- There’s Room to Chase These 3 Stocks Trading Near 52-Week Highs
- Financial Services Stocks Investing
- 3 Stocks With Robust Growth Outlooks Insiders Are Buying
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
